Uniqure NV Cash Flow Conversion Efficiency
Uniqure NV cash flow conversion efficiency. Based on the latest financial reports, Uniqure NV (QURE) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.40 Million) by net assets ($228.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Uniqure NV (2011–2024)
Cash flow conversion efficiency of Uniqure NV from 2011 to 2024. This chart illustrates how Uniqure NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Uniqure NV for real-time trading data and today's change.
Uniqure NV Cash Flow Conversion Ratio Explained
Uniqure NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Uniqure NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Uniqure NV ranked by their cash flow conversion efficiency. Also see how much is Uniqure NV worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allient Inc.
NASDAQ:ALNT
|
0.045x |
|
C&S Paper Co Ltd
SHE:002511
|
0.142x |
|
Redfin Corp
NASDAQ:RDFN
|
-0.240x |
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
0.028x |
|
Savers Value Village, Inc.
NYSE:SVV
|
0.168x |
|
Prosegur
MC:PSG
|
0.009x |
|
Kinpo Electronics Inc
TW:2312
|
-0.025x |
|
MillerKnoll Inc
NASDAQ:MLKN
|
0.046x |
Annual Cash Flow Conversion Efficiency for Uniqure NV (2011–2024)
The table below shows the annual cash flow conversion efficiency of Uniqure NV from 2011 to 2024. Review Uniqure NV (QURE) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.75 Million | $-182.73 Million | 27.063x | +3951.28% |
| 2023-12-31 | $207.67 Million | $-145.93 Million | -0.703x | -130.59% |
| 2022-12-31 | $476.01 Million | $-145.06 Million | -0.305x | -163.05% |
| 2021-12-31 | $595.78 Million | $287.96 Million | 0.483x | +187.44% |
| 2020-12-31 | $243.91 Million | $-134.83 Million | -0.553x | -80.96% |
| 2019-12-31 | $323.06 Million | $-98.68 Million | -0.305x | +27.85% |
| 2018-12-31 | $179.61 Million | $-76.04 Million | -0.423x | +40.75% |
| 2017-12-31 | $89.94 Million | $-64.27 Million | -0.715x | +37.02% |
| 2016-12-31 | $63.63 Million | $-72.19 Million | -1.134x | -889.30% |
| 2015-12-31 | $130.63 Million | $18.78 Million | 0.144x | +124.36% |
| 2014-12-31 | $52.39 Million | $-30.92 Million | -0.590x | +20.61% |
| 2013-12-31 | $7.68 Million | $-5.71 Million | -0.743x | -102.95% |
| 2012-12-31 | $-592.48K | $-14.91 Million | 25.172x | +290.73% |
| 2011-12-31 | $-3.36 Million | $-21.65 Million | 6.442x | -- |
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more